Ibio (IBIO) closed at $0.73 on November 13, 2026, down 4.0% from the previous close, on volume of 436,946 shares (30-day average 694,960).
Data as of November 13, 2026.
Analysts Offer Insights on Healthcare Companies: Talphera (TLPH) and Ibio (IBIO)
TipRanks (Fri, 13-Nov 9:20 AM ET)
iBio GAAP EPS of -$0.05 beats by $0.01, revenue of $1.08M beats by $1.06M
Seeking Alpha News (Tue, 10-Nov 4:34 PM ET)
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 10-Nov 4:30 PM ET)
iBio to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 4:30 PM ET)
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 28-Aug 7:00 AM ET)
iBio’s Spotlight at Guggenheim Healthcare Conference Highlights Strategic Push in Obesity Innovation
Market Chameleon (Thu, 23-Oct 6:34 AM ET)
iBio Showcases Promising Activin E Antibody Data Ahead of Obesity and Cardiometabolic Conferences
Market Chameleon (Wed, 22-Oct 7:09 AM ET)
Market Chameleon (Tue, 21-Oct 6:28 AM ET)
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Ibio trades on the NASDAQ stock market under the symbol IBIO.
As of November 13, 2026, IBIO stock price declined to $0.73 with 436,946 million shares trading.
IBIO has a beta of 2.20, meaning it tends to be more sensitive to market movements. IBIO has a correlation of 0.08 to the broad based SPY ETF.
IBIO has a market cap of $51.55 million. This is considered a Micro Cap stock.
Last quarter Ibio reported $1 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.02.
In the last 3 years, IBIO traded as high as $6.89 and as low as $.56.
The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF, IWC.
IBIO has underperformed the market in the last year with a price return of -41.5% while the SPY ETF gained +11.5%. IBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.2% and -10.1%, respectively, while the SPY returned -2.1% and -1.9%, respectively.
IBIO support price is $.71 and resistance is $.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.